Messina J

References (3)

Title : Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression - Farlow_2001_Arch.Neurol_58_417
Author(s) : Farlow MR , Hake A , Messina J , Hartman R , Veach J , Anand R
Ref : Archives of Neurology , 58 :417 , 2001
Abstract : Farlow_2001_Arch.Neurol_58_417
ESTHER : Farlow_2001_Arch.Neurol_58_417
PubMedSearch : Farlow_2001_Arch.Neurol_58_417
PubMedID: 11255445

Title : Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease - Potkin_2001_Int.J.Neuropsychopharmacol_4_223
Author(s) : Potkin SG , Anand R , Fleming K , Alva G , Keator D , Carreon D , Messina J , Wu JC , Hartman R , Fallon JH
Ref : Int J Neuropsychopharmacol , 4 :223 , 2001
Abstract : Potkin_2001_Int.J.Neuropsychopharmacol_4_223
ESTHER : Potkin_2001_Int.J.Neuropsychopharmacol_4_223
PubMedSearch : Potkin_2001_Int.J.Neuropsychopharmacol_4_223
PubMedID: 11602028

Title : An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors - Kumar_2000_Eur.J.Neurol_7_159
Author(s) : Kumar V , Anand R , Messina J , Hartman R , Veach J
Ref : Eur Journal of Neurology , 7 :159 , 2000
Abstract : Kumar_2000_Eur.J.Neurol_7_159
ESTHER : Kumar_2000_Eur.J.Neurol_7_159
PubMedSearch : Kumar_2000_Eur.J.Neurol_7_159
PubMedID: 10809936